Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Equity Average (2016 - 2025)

Historic Equity Average for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$104.5 million.

  • Northwest Biotherapeutics' Equity Average fell 3347.27% to -$104.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.5 million, marking a year-over-year decrease of 3347.27%. This contributed to the annual value of -$80.1 million for FY2024, which is 1733.89% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Equity Average of -$104.5 million as of Q3 2025, which was down 3347.27% from -$99.9 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Equity Average peaked at -$58.5 million during Q2 2023, and registered a low of -$705.8 million during Q4 2023.
  • For the 5-year period, Northwest Biotherapeutics' Equity Average averaged around -$203.5 million, with its median value being -$104.5 million (2025).
  • Per our database at Business Quant, Northwest Biotherapeutics' Equity Average tumbled by 77725.61% in 2021 and then skyrocketed by 8886.72% in 2024.
  • Northwest Biotherapeutics' Equity Average (Quarter) stood at -$212.9 million in 2021, then skyrocketed by 44.34% to -$118.5 million in 2022, then crashed by 495.69% to -$705.8 million in 2023, then skyrocketed by 87.63% to -$87.3 million in 2024, then dropped by 19.72% to -$104.5 million in 2025.
  • Its Equity Average was -$104.5 million in Q3 2025, compared to -$99.9 million in Q2 2025 and -$97.0 million in Q1 2025.